Metal-organic frameworks (MOFs) are currently widely investigated for a number of potential biomedicinal applications, with particular focus on nanoscale drug delivery. Nanomedicine in general comes with specific challenges to ensure reproducibility of results, including batch-to-batch variations in ostensibly the same nanomaterial, differences in synthetic and analytical practices, intrinsic issues with in vitro culturing and assaying, and a lack of availability of raw data for comparative analysis. This perspective provides an overview of reproducibility issues in the context of MOFs in nanomedicine, covering their preparation and in vitro analysis. The commonly studied UiO-66 is used as an exemplar to highlight variability in synthetic and characterisation practices, as well as in the publication and availability of data. Some common roadblocks to reproducibility are highlighted, alongside suggestions and resources for best practice.

金属有机框架（MOF）目前在许多潜在的生物医学应用中得到广泛研究，特别关注纳米级药物输送。一般来说，纳米医学在确保结果的可重复性方面面临着特定的挑战，包括表面上相同的纳米材料的批次间差异、合成和分析实践的差异、体外培养和测定的内在问题以及缺乏原始数据的可用性进行比较分析。该观点概述了纳米医学中 MOF 的重现性问题，涵盖其制备和体外分析。普遍研究的 UiO-66 被用作范例，以强调合成和表征实践以及数据的发布和可用性方面的可变性。重点介绍了可重复性的一些常见障碍，以及最佳实践的建议和资源。